Sunday, October 4, 2015

Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers by ANDREW POLLACK and SABRINA TAVERNISE


By ANDREW POLLACK and SABRINA TAVERNISE

A pharmaceutical company buys old drugs and increases the price multifold, a profitable business model that is drawing anger and making the traditional drug industry nervous.

Published: October 5, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1hiPwZ3



from WordPress http://ift.tt/1QRU0BV
via Hadi Aboukhater
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)